On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma

Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered 'undruggable', several novel direct KRASG12C inhib...

Descripción completa

Detalles Bibliográficos
Autores: Lindsay, Colin R., Garassino, Marina C., Nadal, Ernest, Öhrling, Katarina, Scheffler, Matthias, Mazières, Julien
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/180608
Acceso en línea:https://hdl.handle.net/2445/180608
Access Level:acceso abierto
Palabra clave:Càncer de pulmó
Oncogens
Immunoteràpia
Lung cancer
Oncogenes
Immunotherapy
id ES_fb802d1d4193fd747f3aa4ab0d77d46e
oai_identifier_str oai:recercat.cat:2445/180608
network_acronym_str ES
network_name_str España
repository_id_str
spelling On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinomaLindsay, Colin R.Garassino, Marina C.Nadal, ErnestÖhrling, KatarinaScheffler, MatthiasMazières, JulienCàncer de pulmóOncogensImmunoteràpiaLung cancerOncogenesImmunotherapyNon-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered 'undruggable', several novel direct KRASG12C inhibitors have shown encouraging signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by the US Food and Drug Administration. This review examines the role of KRAS mutations in NSCLC and the challenges in targeting KRAS. Based on specific KRAS biology, it reports exciting progress, exploring the use of novel direct KRAS inhibitors as monotherapy or in combination with other targeted therapies, chemotherapy, and immunotherapy.Elsevier BV2021202120212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion14 p.application/pdfapplication/pdfhttps://hdl.handle.net/2445/180608Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1016/j.lungcan.2021.07.005Lung Cancer, 2021, vol. 160, p. 152-165https://doi.org/10.1016/j.lungcan.2021.07.005cc by (c) Lindsay, Colin R. et al., 2021http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1806082026-05-29T05:05:01Z
dc.title.none.fl_str_mv On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
title On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
spellingShingle On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Lindsay, Colin R.
Càncer de pulmó
Oncogens
Immunoteràpia
Lung cancer
Oncogenes
Immunotherapy
title_short On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
title_full On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
title_fullStr On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
title_full_unstemmed On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
title_sort On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
dc.creator.none.fl_str_mv Lindsay, Colin R.
Garassino, Marina C.
Nadal, Ernest
Öhrling, Katarina
Scheffler, Matthias
Mazières, Julien
author Lindsay, Colin R.
author_facet Lindsay, Colin R.
Garassino, Marina C.
Nadal, Ernest
Öhrling, Katarina
Scheffler, Matthias
Mazières, Julien
author_role author
author2 Garassino, Marina C.
Nadal, Ernest
Öhrling, Katarina
Scheffler, Matthias
Mazières, Julien
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Càncer de pulmó
Oncogens
Immunoteràpia
Lung cancer
Oncogenes
Immunotherapy
topic Càncer de pulmó
Oncogens
Immunoteràpia
Lung cancer
Oncogenes
Immunotherapy
description Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered 'undruggable', several novel direct KRASG12C inhibitors have shown encouraging signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by the US Food and Drug Administration. This review examines the role of KRAS mutations in NSCLC and the challenges in targeting KRAS. Based on specific KRAS biology, it reports exciting progress, exploring the use of novel direct KRAS inhibitors as monotherapy or in combination with other targeted therapies, chemotherapy, and immunotherapy.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/180608
url https://hdl.handle.net/2445/180608
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.lungcan.2021.07.005
Lung Cancer, 2021, vol. 160, p. 152-165
https://doi.org/10.1016/j.lungcan.2021.07.005
dc.rights.none.fl_str_mv cc by (c) Lindsay, Colin R. et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Lindsay, Colin R. et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 14 p.
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier BV
publisher.none.fl_str_mv Elsevier BV
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425334498099200
score 15,812429

Similares en LA Referencia